Market Research Blog

Global demand for loop-mediated isothermal amplification technology reached around US$ 85 million in 2018, as indicated by a new research study of Future Market Insights (FMI). Estimated to observe stable growth in revenue over the coming years, loop-mediated isothermal amplification market will witness dominance of DNA polymerase, among the various product types.

A new study of Future Market Insights (FMI) indicates that the global general anesthesia drugs market is poised for steady growth in the years ahead. Today, the general anesthesia drugs market remains driven by increased proportion of elderly patients and rising volume of surgical procedures; FMI analyst forecasts the market to witness 3.5% CAGR during the period, 2019-2029.

The aromatherapy market is estimated to be valued at ~US$ 4.6 Bn in 2019, unveils the new research study by Future Market Insights (FMI). According to the report, the aromatherapy market is projected to grow by ~7% YOY in 2020, primarily influenced by greater emphasis on good health and wellness.

Prominent Players:

• Young Living Essential Oils,
• Do TERRA,
• Mountain Rose Herbs,
• Edens Garden,
• Frontier Natural Products Co-op,
• Rocky Mountain Oils,
• Plant Therapy Essential Oils,
• First Natural Brands LTD.
• (Tisserand), and Soulflower.

Added Benefits of Essential Oils for Various Ailments Aiding the Market Growth

Aromatherapy acts as a complementary treatment in many viral and bacterial diseases such as acute respiratory infections, viral infections, influenza, and bronchitis. Aromatherapy can be used during prophylactic and therapeutic treatment regimens for many diseases such as Initial forms of atherosclerosis, coronary heart disease, neuro-dystonia, hypertension, hypotension, anxiety, depression, insomnia and many such disorders. Thus, added benefits and applications of essential oils in many indications will continue to account for greater gains in the aromatherapy market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1080

Aromatherapy – A Preferred Therapy to Improve Quality of Life

Studies have been conducted to prove the effectiveness of essential oils that support the body to heal. Essential oils such as thyme, rosemary, oregano, chamomile, and frankincense are used for the treatment of certain benign tumors to selectively harm or disable cancer cells while leaving healthy cells intact. Increasing inclination towards natural remedies provides good growth opportunities for players in the essential oil industry in the near future. Also, presently aromatherapy has been used for cancer patients as it reduces anxiety levels and relieves emotional stress, pain, muscular tension, and fatigue after chemotherapy or post radiation therapy.

Risk Factors Associated with Aromatherapy Restricting Market Growth

Some risk factors and complications are associated with aromatherapy as individuals have unique metabolism, vitality, and physical makeup. Therefore, acceptable dose for one may not be appropriate for others. Risk factors such as toxicity, skin sensitization, photosensitivity etc. have been reported with patients undergoing aromatherapy. However, many essential oils are contraindicated for use during pregnancy and breast-feeding due to their abortifacient properties. Thus, increasing apprehensions regarding the risks of essential oils and other complications result in low preference and reluctance for undergoing aromatherapy by patients, which in turn restrains revenue growth of the aromatherapy market to a certain extent.

Key Segment

Product

• Consumables
  • Essentials Oil
• Floral
• Citrus
• Herbaceous
• Spicy
• Woodsy
• Earthy
• Camphhorous
• Others
  • Blended Oils
  • Carrier Oils
• Equipment
  • Nebulizing Diffuser
  • Ultrasonic Diffuser
  • Evaporative Diffuser
  • Heat Diffuser

Application

• Relaxation
• Insomnia
• Pain Management
• Scar Management
• Skin & Hair Care
• Cold & Cough
• Others

Mode of Delivery

• Topical Application
• Direct Inhalation
• Aerial Diffusion

For in-depth insights, Download a PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1080

Distribution Channel

• Retail Shops
• Online Channel
• Direct Distribution

Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East and Africa

As per Future Market Insights (FMI), driven by rising cases of cancer and cardiovascular diseases, radiopharmaceutical market registered steady year-on-year growth at 4.90% CAGR in 2021.

Increasing development of radioisotopes to curb the cases of cancer have propelled the market demand, topping a valuation of US$ 6,107.2 Mn in 2021. Rising cases of prostate and breast cancer, especially in developed countries including the U.S., the U.K., and Germany, have increased the application of radiopharmaceuticals.

Government initiatives and research activities undertaken to develop advanced radioisotopes for the treatment of cancer and to develop novel therapeutics will boost the demand. Also, introduction of novel technologies such as Positron Emission Technology and others in nuclear imaging systems will bolster growth.

However, due to the global shutdown witnessed in the FQ-20 in response to the COVID-19 outbreak, growth declined considerably. Suspended production of radioisotopes and disruption in the research activities delayed the deployment of projects in the healthcare sector.

Although, with increasing development activities and increasing commercialization of radiopharmaceuticals by industry giants have picked up the pace for the growth of market. Alongside this, increasing cases of cancer will accelerate the development of nuclear medicines in the field of radiopharmaceuticals.

To remain ‘ahead’ of your competitors, request for a sample

Increasing preference of non-invasive medical therapies and production of radioisotopes for the treatment is another factor that will stabilize the growth of radiopharmaceuticals market. Based on this, FMI projects the market is poised to expand at over 4.66% CAGR during the forecast period of 2021 and 2031.

Prominent Players:

Siemens AG

Positron Corporation

Novartis (Advanced Accelerator Applications)

Curium

GE Healthcare

Lantheus Holdings Inc.

Sotera Health LLC

Bayer AG

Eckert & Ziegler

Key Takeaways from FMI’s Radiopharmaceuticals Market Study

In terms of application, oncology will contribute over 50% of global market share owing to the rising prevalence of cancer across the globe.

Cyclotrons are expected to be the primary source of radiopharmaceuticals, accounting for maximum market share

Based on radioisotope type, technetium-99 will remain highly preferred radioisotope in the global radiopharmaceutical market

The U.S. will retain its global dominance backed by the high cancer and cardiovascular cases rising in the country

India will emerge as lucrative market owing to the favorable government initiatives promoting the radiopharmaceuticals market

Germany and the U.K. are spearheading the growth of Europe market, which is projected to grow at over 4.9% CAGR

“Increasing research and development initiatives aimed at the production of advanced radioisotopes and novel technologies will improve growth prospects for the leading players in the radiopharmaceuticals market,” says the FMI analyst.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1992

Competitive Landscape

Leading radiopharmaceuticals market players are focusing on expanding their customer base through strategic mergers and acquisition. Increasing research and development activities to develop advanced radioisotopes for the cancer treatment is another core strategy adopted by leading players.

Top 5 players including Siemens AG, GE Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler are dominating the global radiopharmaceuticals market, contributing over 90% of revenue share.

In March 2021, Novartis announced the commercialization and obtained the rights to develop the therapeutic applications of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Along with it the company announced the production and commercialization of new nuclear medicine, 18F sodium fluoride radiopharmaceutical in France.

In November 2020, Blue Earth Diagnostics, a leading molecular imaging diagnostic company, unveiled that their manufacturing company, Nucleis has manufactured and shipped their first doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, for patients with prostate cancer.

Another industry giant, Jubilant Pharma Limited Company, in 2019, announced the integration of its radiopharmaceutical drug development and manufacturing business with its radio-pharmacy business into a global radiopharmaceutical brand, Jubilant Radiopharma.

Radiopharmaceuticals Market by Category

By Radioisotope Type:

Technetium-99

Fluorine-18

Iodine-131

Leutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

By Application:

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

By Source:

Cyclotrons

Nuclear Reactors

For in-depth competitive analysis Buy Now – https://www.futuremarketinsights.com/checkout/1992

By End-User:

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific excluding Japan

Japan

Middle East & Africa (MEA)

Anaesthesia Conduction Kits Market Overview

Anesthesia Conduction Kits: Market Insights

Anesthesia Conduction Kits is a device which is used to administer to patient conduction, local and regional anesthesia. Conduction Anesthesia in which anesthetic solution is injected in nerves to prevent nerve transmission which include nerve block and field block, spinal and  epidural anesthesia. Conduction anesthesia in which there is loss of sensation, produced by injecting local anesthesia along the course of a nerve or nerves to prevent the conduction of impulses to and from the area supplied by that nerve or nerves. Anesthesia conduction kits primarily include needles, syringes and catheter. Conduction anesthesia involves the introduction of drugs which block the nerve supply to the specific part of the body. Regional anesthesia is achieved by using local anesthesia drugs which block nerve conduction. Anesthesia conduction is given during the surgical procedure which reduce regional blood flow by single injection with catheter to allow intermittent boluses or continuous infusion.

Anesthesia Conduction Kits: Market Dynamics

Increased in number of surgeries across the globe, development of new anesthetic and sedative drugs, reduction in cost of new invested drugs and decreased recovery time after surgery are the major factor which drive the market of anesthesia conduction kits market globally. Further increase incidence of old age population and rising number of emergency surgeries globally in public and private sector boost the market of anesthesia conduction kits market. Moreover, government support and increase research and development in drug development and increase in healthcare expenditure provide opportunity for anesthesia conduction kits market. Side effects and low adoption rate of anesthesia conduction in under developed and developing countries and lack of skilled physicians in low or middle income countries hinder the growth of anesthesia conduction kits market.

Anaesthesia Conduction Kits: Overview

Rapid advancement in the anesthesia industry and development of new drugs, rapid urbanization upsurge of number of surgeries, growth in ageing population majorly drive the overall anesthesia conduction kits market. Improvement in healthcare industry owing to increasing number of medical professionals and growing awareness and use of anesthesia drug in different types of surgeries propel the growth of anesthesia conduction kits market. Hospital accounts for the largest revenue share owing to more number of use of anesthesia conduction kits in surgeries such as cardiovascular, spinal.

Anaesthesia Conduction Kits: Region-wise Outlook

On the basis of geography, global anesthesia conduction kits is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest shares in the global anesthesia conduction kits due to growing number of emergency and general surgeries, increasing cardiovascular and respiratory disease and rising ageing population. Advancement in development of new anesthesia drugs are prime factor which drive the market of anesthesia conduction kits. Europe is anticipated to be the second in the revenues share. Asia Pacific region is anticipated to be the fastest growing region in anesthesia conduction kits market owing to increase in investment in the research and development in the drug development and government initiative towards the improvement of healthcare expenditure. Latin America and Middle East & Africa is expected to show slow growth owing to lack of killed anesthetists to administer the drugswith anesthesia conduction kits in near future.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7037

Anaesthesia Conduction Kits: Key Players

Some of the key players present in global anaesthesia conduction kits are B. Braun Medical Inc., Epimed International, Smiths Medical, BK Ultrasound, Teleflex Incorporated, Guangdong Baihe Medical Technology Co., Ltd, Bionic Medizintechnik GmbH, Koninklijke Philips N.V, Biomedical Srl and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request a Complete TOC of this Report with figures:
https://www.futuremarketinsights.com/toc/rep-gb-7037

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

The digital pathology market has witnessed notable changes in terms of product innovation. One of the major reasons behind this is the scope of cloud integration with pathology outcomes in laboratory operations. According to a recent report by Future Market Insights, the global digital pathology market was valued at USD 6.19 Bn in 2021 and is expected to witness a CAGR of 13.5% during the forecast period (2021 – 2031).

The scope of digital pathology with cloud integration has expanded with promising potential for numerous therapies in the healthcare industry including anti-cancer treatments. Innovation in terms of product efficiency, capabilities, and other modalities drives growth in the digital pathology market.

A number of modern hospitals are installing newly modified digital pathology systems for their laboratories which has widened the consumer base of the market globally. Manufacturers of digital pathology solutions are constantly making changes in software, to enhance the capabilities and efficacies of digital pathology devices.

This development will provide easy access to information such as images, and will also cater to specialized needs. In 2017, Glencoe Software Inc., launched a software named Path Viewer, which is used in interactive viewing and annotation of digital pathology images.

In Jan 2018, Definiens AG released Tissue Studio 4.2 software package. The updated product suite provided improved image analysis for researchers in academic medical laboratories, comprehensive cancer diagnostic and treatment centers, biotechnology, and pharmaceutical companies.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-124

Key Takeaways of Digital Pathology Market Study

Digital pathology equipment is anticipated to increase at a CAGR of 13.7% over 2021-2031, to reach US$ 12.94 Bn by 2031, aided by growing investments by hospitals and laboratories. The clinical pathology and molecular diagnostics segment collectively have gained more than 50% of the market share in terms of revenue owing to use for a wider scope of ailments. CROs are estimated to display high growth potential at a CAGR of 19.0% in the forecast period owing to cost benefits to end users. Canada is reflecting high potential for growth with a 14.2% CAGR, driven by the expansion of urban centers and investments into healthcare facilities. The U.K. will account for over 24% of the Europe value share, surpassing Germany by 2031, owing to increases in healthcare research spending. “Growing research and development initiatives aimed towards cancer diagnosis and treatment are key factors expected to provide major growth opportunities for the digital pathology market through the end of 2031,” says the FMI Analyst.

Who is Winning?

Leading players in the market are largely focused on product development launches in addition to investing in strategic acquisitions and capacity expansions, to explore previously untapped markets.

Some the prominent players in the digital pathology market are Danaher Corporation, F. Hoffmann-La Roche AG, Huron Technologies International Inc., Koninklijke Philips N.V., Olympus Corporation, Hamamatsu Photonics K.K., Carl Zeiss, 3D HISTECH Ltd.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029. The study provides compelling insights on digital pathology market on basis of component type (systems, software, and services), application (clinical pathology, molecular diagnostics, basic & applied research, drug development, others) and end users (hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, forensic laboratories, research institutes, contract research organizations, and clinics across seven major regions.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-124

key segment

By Product Type:

Equipment

Whole Slide Scanners

Brightfield Slide Scanners

Fluorescence Slide Scanners

Combination Slide Scanners

Clinical Microscope

Tissue Microarrays Softwares

Image Viewing and Analysis Softwares

On-premise

Cloud-based

Digital Pathology Information Systems

On-premise

Cloud-based

Services

Installation and Integration Services

Consulting Services

Maintenance and Validation Services

By Application:

Clinical Patholog Molecular Diagnostics Basic & Applied Research Drug Development Others

End-User:

Hospitals

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Forensic Laboratories

Research Institutes

Contract Research Organizations (CROs)

Clinics

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/124

Region:

North America

Latin America

Europe

East Asia

South Asia & Pacific

The Middle East and Africa (MEA)

Increasing contact lens usage, emerging new treatment options such as anti-amoebic drugs, and well-established supply chain operations are expected to fuel the growth of the corneal ulcer treatment market. Various initiatives by global as well as regional organizations, governments, etc., to eliminate avoidable blindness caused due to contact lens use, are helping to increase awareness about corneal ulcer among the general public as well as ophthalmologists. Further, universities and non-profit organizations arranging eye check-up camps further aids in enhancing awareness about corneal ulcers.

Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year. The incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.

The global PARP inhibitors market is estimated to be valued at US$ 8.4 Bn by 2026, expanding at a significant CAGR from 2019 to 2026.

“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period.”

Key Takeaways of PARP Inhibitors Market Study

Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2018, and will continue to do so during the forecast period.

PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.

Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence

All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings. For example, in January 2019, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).

More Valuable Insights on PARP Inhibitors Market

Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2015 to 2026. The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provide compelling insights on PARP inhibitors market on basis of drug (Olaparib, Niraparib, Rucaparib, and Talazoparib), indication (ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer), and distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), across seven major regions.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-3197

PARP INHIBITORS MARKET TAXONOMY

The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug

• Olaparib
• Niraparib
• Rucaparib
• Talazoparib

Indication

• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

North America

Europe

Latin America

South Asia

East Asia

Oceania

Middle East And Africa

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-3197

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

[250 Pages Report] The rising prevalence of respiratory disorders has necessitated innovation in manufacture of respiratory inhalers. The demand for better precision in drug delivery is enabling broader adoption of Respiratory Inhaler Devices, especially among patients of asthma and chronic obstructive pulmonary diseases (COPD). Steady growth is expected to continue as favorable reimbursement policies by governments create a conducive environment around the world.

Global respiratory inhaler device shipments are likely to grow at over 4% in 2021, as the medical device industry makes a gradual recovery. Innovation in smart inhaler technologies is likely to be a key focus area, but manual inhalers will still account for 90% of total demand. This stark contrast reflects the status-quo in the global medical device industry, where realization of new investment and bottom-lines are concurrent.